The Federal Government has published the following proposed amending regulations in Part 1 of the Canada Gazette:
- Regulations Amending the Food and Drug Regulations (Exports and Transhipments of Drugs): The amendments would extend drug establishment licensing and Good Manufacturing Practices (GMP) requirements to persons conducting licensable activities with drugs solely for export. Additionally, the proposed amendments would also clarify that drugs in transhipment through Canada must be in bond. Consultation on the proposed amendments is open until August 26, 2021.
- Regulations Amending the Natural Health Products Regulations: As per Health Canada’s news release, the proposed amendments seek to make natural health product labels more clear, legible, and easier to understand. Consultation on the proposed amendments is open until September 4, 2021.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada finalizes biosimilar guidance: comparative clinical efficacy studies not typically required
In Canada, biosimilar products are approved by way of a new drug submission, following Health Canada guidance first released in 2010 and significantly revised in 2016.Read More -
2026 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2026, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top storiesRead More -
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More
